View printer-friendly version
« Back
August 05, 2004 5:14 p.m.
Teva and Savient Receive Favorable Court Ruling on Human Growth Hormone Patent Suits

Jerusalem, Israel, August 5, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) today announced that the United States District Court for the District of Delaware has found invalid and unenforceable due to inequitable conduct, Novo Nordisks (NYSE:NVO) U.S. Patent No. 5,633,352 relating to recombinant human growth hormone. This ruling, which follows the completion of a trial in August 2003, paves the way for the U.S. commercialization of Savients FDA approved recombinant human growth hormone.

Savients recombinant human growth hormone for the treatment of growth hormone deficiency in children is marketed in over 30 countries worldwide and is licensed to Teva for distribution in the United States. The U.S. pediatric market for recombinant human growth hormones is approximately $500 million and currently growing at an annual rate of 12%.

Christopher Clement, President and CEO of Savient stated: This is excellent news. We are very pleased with the District Courts ruling that Novos patent is invalid and unenforceable. With the clarity provided by these decisions, we will proceed with our plans to bring our human growth hormone to market in the United States later this year. We have every confidence in Tevas ability to establish a significant presence in the market once Tev-Tropin is introduced.

Israel Makov, President and CEO of Teva commented: We are gratified by this recent Court decision. We will now work with our partner Savient to take the necessary steps to prepare ourselves for the launch of this product.


Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Tevas sales are in North America and Europe.



Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva's ability to rapidly integrate the operations of acquired businesses, including its recent acquisition of Sicor Inc., the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.